Urigen Pharmaceuticals
305 East High Street
Suite 7
Bound Brook, NJ 08805
United States
ph: 732-369-5911
Presently, the only approved products for treating interstitial cystitis / bladder pain syndrome (IC/BPS) in the US and Europe, are based on clinical studies which have shown the drugs to be marginally effective. Consequently, there remains a significant need for new therapeutic interventions such as URG101 that can address the underlying disease process while also providing acute symptom relief.
Copyright 2020 Urigen . All rights reserved.
Urigen Pharmaceuticals
305 East High Street
Suite 7
Bound Brook, NJ 08805
United States
ph: 732-369-5911